SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

Tron is trending amidst discussions about its potential Nasdaq listing via a reverse merger, alongside its existing ties to Rumble and Tether. Community members are weighing the potential benefits of increased exposure versus concerns about centralization and regulatory scrutiny. Ongoing developments with Keeta Network as a possible competitor are also being actively discussed.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-secured meme coin, sparking community excitement around its potential to outperform competitors like $DOGE.X. Many believe its direct link to Bitcoin's blockchain and fair launch give it a unique advantage, fueling discussions about its role as a cultural and economic driver within the Runes ecosystem.

ZoraAI agents are designed to take the complexity out of everyday tasks, leaving you with more time and energy to focus on what matters most. With their powerful automation and adaptability, your life and work will become more efficient and effortless. With ZoraAI, you’re in control. The customizable agents feature lets you mix and match your favorite tools and capabilities from different agents to build one that’s perfectly tailored to your needs. Whether you want a multitasking powerhouse or a focused specialist, your personalized agent is designed to work exactly how you want it to—no coding required.

Zoracles

Zoracles ($ZORA.X) is trending as a social media token coin, newly listed on Coinbase, which is generating buzz among traders. The community is actively discussing its potential as the 'Instagram of crypto', focusing on its ability for creators to monetize content and the possibility of a significant price surge. Some traders are wary of pump and dump schemes, while others believe in its long-term potential and are closely watching resistance levels.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors discuss its potential within the AI-driven marketing landscape and debate its current valuation. Community members are weighing positive earnings against a lawsuit and overall market conditions, with some anticipating a rise to the $20-$30 range while others remain skeptical. There's active discussion around institutional ownership, potential buybacks, and its competitive positioning against larger players like Salesforce.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

Shares of GYRO are trending due to a potential run driven by its low float and recent news regarding a land sale, which investors believe could significantly increase its NAV. The community is closely watching for a breakout, drawing comparisons to other low-float runners and discussing potential price targets amid building momentum. Some traders are drawn to the stock's meme potential given its name.

Numeraire

Numeraire is trending with community members highlighting its potential for significant gains, referencing a possible investment from a major US bank and the token's low circulating supply. Some traders are pointing to technical indicators like double bottom formations and unusual buying pressure, while others suggest it may be exhibiting pump and dump characteristics. The discussions also reflect interest in Numerai's integration with AI and decentralized finance.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is trending amid discussions of gold's potential rally and anticipation of upcoming earnings reports from gold miners. The community is weighing factors like central bank policies, inflation, and geopolitical tensions, with some predicting significant upside for gold and related assets. Technical analysis, particularly Elliott Wave patterns, is being used to gauge potential entry and exit points.

WorldFinancial

WorldFinancial ($WLFI.X) is trending amidst community discussions around recent price volatility and speculation about its connection to Justin Sun. Some community members suggest potential manipulation, while others highlight the project's fundamentals and its association with prominent figures. The conversation also includes mentions of potential partnerships and developments in the broader crypto space.

USELESS

$USELESS.X is gaining attention as community members discuss its potential for substantial gains, with some pointing to accumulation by whales. The coin's intentionally ironic name and the community's embrace of its 'uselessness' are also points of discussion.  Additionally, some users suggest that a similar coin, $GASH.X, may also see similar gains.

Sui is an innovative layer-1 blockchain platform crafted to meet the demands of global adoption, providing a secure, robust, and scalable development environment. Rooted in a unique object-centric data model and fortified by the trusted Move programming language, Sui is engineered to tackle the inefficiencies found in current blockchain frameworks.  In addition to its solid technical underpinnings, Sui places a strong emphasis on user experience, aiming to remove common barriers encountered in blockchain interactions. Through groundbreaking features such as zkLogin, sponsored transactions, and programmable transaction blocks, Sui sets a new standard for user accessibility and friendliness within Web3 applications.  Unique elements of Sui Sui’s innovative architecture ensures swift transactions with stable fees and high throughput through horizontal scaling. Its object-oriented design offers deep composability for developers, enabling tailored object types with network-wide compatibility. This revolutionizes asset and protocol collaboration, fostering product innovation.  The platform's object-oriented approach dramatically improves transaction processing, enabling parallel execution and faster completion times. Additionally, unique consensus requirements expedite transaction finalization while maintaining stability. Sui prioritizes overcoming Web3 adoption barriers, offering native tools like zkLogin and sponsored transactions for wallet onboarding and fee management.  Move integration into Sui's data model combines innovation with security, mitigating common exploits found in smart contract languages. This empowers developers and users with a secure and intuitive platform, accelerating the evolution of Web3 applications.  About the Sui token The SUI token serves four primary functions within the Sui ecosystem: Proof-of-stake participation - Sui implements a delegated proof-of-stake mechanism, rewarding honest behavior by validators and SUI token holders who stake with them. Gas fee payments - SUI tokens cover gas fees for executing transactions and storing data onchain. Application utility - SUI is a versatile asset, integral to various applications within Sui’s ecosystem, including decentralized exchanges, lending platforms, gaming, and more. Governance - The SUI token empowers holders to participate in on-chain voting on significant matters like protocol upgrades and platform changes, shaping the future of Sui.  Additionally, the Sui storage fund ensures fair compensation for validators by distributing stake rewards over time and covering storage costs for previously stored on-chain data. This tokenomic strategy promotes indefinite data storage while maintaining fair compensation for validators, fostering long-term sustainability.

SUI.X is trending as the community anticipates a potential breakout, fueled by discussions of new partnerships and increased adoption. Community members are actively comparing SUI to Solana, highlighting its unique architecture and scalability, while expressing excitement about its potential for growth. Speculation around institutional investment and upcoming catalysts like potential rate cuts are contributing to the positive sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The U.S. Food and Drug Administration (FDA) announced on Thursday that it is withdrawing its approval of the new drug application (NDA) for Amylyx Pharmaceuticals’ (AMLX) Relyvrio.Amylyx has voluntarily requested that the FDA withdraw approval of this application and has waived its opportunity for a hearing, the agency <a target="_blank" rel="noopener noreferrer nofollow" href="https://public-inspection.federalregister.gov/2025-16646.pdf">said</a>. The FDA approved the application for Relyvrio for the treatment of amyotrophic lateral sclerosis (ALS) in adults in September 2022. Amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, is a progressive, fatal neurodegenerative disorder that causes muscle weakness and paralysis by destroying motor neurons, the cells that control voluntary muscle movement.&nbsp;However, last year, the company reported to the agency that a late-stage trial evaluating the drug in patients living with ALS did not meet its prespecified goals. It also notified the agency that it plans to discontinue marketing of Relyvrio as of Oct. 31, 2024.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AMLX">AMLX stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_2_17_49_PM_png_ec4ad4caa5.webp" alt="AMLX's Sentiment Meter and Message Volume as of 2:18 p.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>AMLX's Sentiment Meter and Message Volume as of 2:18 p.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company <a href="https://stocktwits.com/news-articles/markets/equity/amylyx-discontinues-investigative-therapy-program-in-rare-neurological-disorder/chsUG7LRdkv">reiterated</a> earlier this week that it has a cash runway until the end of 2026 on the heels of discontinuing its AMX0035 program in adults living with progressive supranuclear palsy.The decision to discontinue the program was made after it failed to show differences compared to the placebo on primary or secondary outcomes at week 24 in a mid-stage trial. The company will not initiate the late-stage portion of the program, it then said.AMLX stock is up 148% this year and approximately 349% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/li-auto-announces-lower-q3-delivery-outlook-despite-new-vehicle-launches/chs60e1RdZ2">Li Auto Announces Lower Q3 Delivery Outlook Despite New Vehicle Launches: Retail Sees i8, i6 Selling Like ‘Hot Cakes’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target

Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.

Equity

Amylyx Pharmaceuticals Inc. (AMLX) on Wednesday said that it is discontinuing its AMX0035 program in adults living with progressive supranuclear palsy.AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol. The decision to discontinue the program was made after it failed to show differences compared to the placebo on primary or secondary outcomes at week 24 in a mid-stage trial. The company will not initiate the late-stage portion of the program, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.amylyx.com/news-releases/news-release-details/amylyx-pharmaceuticals-discontinue-orion-program-amx0035">said</a>.Progressive Supranuclear Palsy (PSP) is a rare, progressive neurological disorder characterized by problems with balance, eye movements, speech, and swallowing, often leading to frequent and unpredictable falls. According to Amylyx, the disease affects about seven in 100,000 people worldwide.On Stocktwits, retail sentiment around the <a href="https://stocktwits.com/symbol/AMLX">AMLX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels. Shares of the company are down by 2% in the pre-market session.“While we are disappointed in these results, we believe these data will inform the PSP trial literature as well as deepen scientific understanding of this devastating disease,” said Camille L Bedrosian, Chief Medical Officer at Amylyx.Co-CEOs of Amylyx, Joshua Cohen and Justin Klee, said that the company’s priority remains on the late-stage trial of Avexitide, with enrollment expected to be completed in 2025 and topline data anticipated in the first half of 2026.Avexitide is an investigational, glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism.The company is also continuing development of AMX0035 in Wolfram syndrome, a rare, inherited genetic disorder, they said. Amylyx continues to expect its cash runway to extend through the end of 2026.AMLX stock is up by 142% this year and has jumped 330% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder

The decision to discontinue the program was made after AMX0035 did not show differences compared to placebo on primary or secondary outcomes at week 24 in a mid-stage trial.

Amylyx Pharmaceuticals&nbsp;drew increased retail attention late Sunday after new clinical data presented at ENDO 2025 highlighted the potential of its lead candidate, avexitide, to significantly reduce dangerous blood sugar drops in patients with post-bariatric hypoglycemia (PBH).In a Phase 2b trial, avexitide 90 mg once daily, the dose being studied in the pivotal Phase 3 Lucidity trial, led to a 64% least-squares mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events.&nbsp;More than half of the participants experienced no severe events during the treatment period.Avexitide is a treatment being developed for post-bariatric hypoglycemia, a condition that currently has no approved therapies. Backed by FDA Breakthrough Therapy designation, the once-daily pill is designed to block the GLP-1 receptor and help prevent dangerous blood sugar drops.&nbsp;New data shared at ENDO 2025 showed that the 90 mg dose maintained steady, around-the-clock activity.&nbsp;A Phase 3 study called Lucidity is now underway, with plans to enroll about 75 people who’ve previously undergone gastric bypass surgery.&nbsp;Amylyx expects to finish signing up participants in 2025 and release the results in the first half of 2026.The data and trial momentum come amid fresh bullish coverage from Wall Street.&nbsp;Goldman Sachs resumed coverage on Amylyx with a ‘Buy’ rating and $10 price target, citing avexitide’s "blockbuster" potential.&nbsp;Guggenheim also started coverage last month with a ‘Buy’ and a $17 target, calling PBH a “not-so-rare” endocrine disease with 50,000–100,000 moderate-to-severe patients in the U.S.&nbsp;Citi joined with a ‘Buy’ and $12 target, highlighting multiple late-stage programs and "clear" clinical endpoints across four high-unmet-need indications.On Stocktwits, retail sentiment for Amylyx was ‘bullish’ amid ‘high’ message volume.Amylyx’s stock has risen 96.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/crinetics-pharma-s-oral-drug-shows-lasting-relief-for-acromegaly-patients-in-latest-study-retail-buzz-builds/ch8B1oBR5Nq">Crinetics Pharma’s Oral Drug Shows Lasting Relief For Acromegaly Patients In Latest Study; Retail Buzz Builds</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Amylyx Pharmaceuticals (AMLX) highlighted the potential of its lead candidate avexitide to significantly reduce dangerous blood sugar drops in patients with post-bariatric hypoglycemia. (Photo credit: Getty Images)

Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial

The company is advancing the treatment into a Phase 3 study with results expected in 2026. 

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High?

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that management will participate in the following upcoming investor conferences, which are being conducted...

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) will report its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025. Amylyx senior management team will...

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced that Amylyx management will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference. The...

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial...

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (Amylyx or the Company) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public offering price...

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

AMLX
Amylyx Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMLX News

AMLX Amylyx Pharmaceuticals Inc